These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25213055)

  • 1. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.
    Morgan M; Cooke A; Rogers L; Adams-Huet B; Khan DA
    J Allergy Clin Immunol Pract; 2014; 2(5):601-6. PubMed ID: 25213055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria.
    Engin B; Ozdemir M
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):481-6. PubMed ID: 18081753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
    Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
    J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.
    Erbagci Z
    J Allergy Clin Immunol; 2002 Sep; 110(3):484-8. PubMed ID: 12209099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria.
    Wan KS; Chang YS
    J Dermatolog Treat; 2014 Dec; 25(6):459-61. PubMed ID: 24192062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria.
    Wan KS
    J Dermatolog Treat; 2009; 20(4):194-7. PubMed ID: 19085267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary regarding Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria by M Morgan, A Cooke, L Rogers, B Adams-Huet, DA Khan. J Allergy Clin Immunol Pract 2:601-606, 2014.
    Yancey KB
    Dermatol Ther; 2015; 28(2):102-3. PubMed ID: 25649343
    [No Abstract]   [Full Text] [Related]  

  • 9. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
    Ring J; Hein R; Gauger A; Bronsky E; Miller B
    Int J Dermatol; 2001 Jan; 40(1):72-6. PubMed ID: 11277962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
    Ortonne JP; Grob JJ; Auquier P; Dreyfus I
    Am J Clin Dermatol; 2007; 8(1):37-42. PubMed ID: 17298105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.
    Maurer M; Mathias SD; Crosby RD; Rajput Y; Zazzali JL
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):641-647. PubMed ID: 29567359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
    Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
    Dubertret L; Murrieta Aguttes M; Tonet J
    J Eur Acad Dermatol Venereol; 1999 Jan; 12(1):16-24. PubMed ID: 10188144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria.
    Brostoff J; Fitzharris P; Dunmore C; Theron M; Blondin P
    Allergy; 1996 May; 51(5):320-5. PubMed ID: 8836336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study.
    Boonpiyathad T; Sangasapaviliya A
    Eur Ann Allergy Clin Immunol; 2017 Sep; 49(5):220-224. PubMed ID: 28884989
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
    Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
    Nelson HS; Reynolds R; Mason J
    Ann Allergy Asthma Immunol; 2000 May; 84(5):517-22. PubMed ID: 10831005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
    Monroe E; Finn A; Patel P; Guerrero R; Ratner P; Bernstein D;
    J Am Acad Dermatol; 2003 Apr; 48(4):535-41. PubMed ID: 12664016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.